Yarrow Bioscience, Inc. (VYNE) CEO lists 878,194-share stock option from merger
Rhea-AI Filing Summary
Yarrow Bioscience, Inc., formerly VYNE Therapeutics Inc., reports Chief Executive Officer Rebecca Frey’s initial beneficial ownership consisting of a stock option to purchase 878,194 shares of common stock at an exercise price of $6.1900 per share, expiring on 2036-01-30, received in connection with a merger and subject to a multi‑year vesting schedule.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Frey Rebecca
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1, F2, F3 | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 878,194 shares (Direct)
Footnotes (3)
- F1. Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").
- F2. Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.
- F3. This option represents a right to purchase 878,194 shares of Issuer Common Stock, one quarter of which will vest on January 16, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Underlying shares: 878194.0000 shares
Exercise price: $6.1900 per share
Option expiration date: 2036-01-30
+2 more
5 metrics
Underlying shares
878194.0000 shares
Shares of Issuer Common Stock underlying reported stock option
Exercise price
$6.1900 per share
Exercise price of the reported stock option
Option expiration date
2036-01-30
Expiration date of the reported stock option
Initial vesting date
2027-01-16
Date when one quarter of the option vests, subject to continued service
Remaining vesting period
3 years
Remaining three quarters vest in equal monthly installments over three years
Key Terms
Effective Time, wholly owned subsidiary, Issuer Common Stock, vesting, +1 more
5 terms
Effective Time regulatory
"Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
wholly owned subsidiary financial
"a wholly owned subsidiary of VYNE Therapeutics Inc. merged with and into"
A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.
Issuer Common Stock financial
"Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock")"
vesting financial
"one quarter of which will vest on January 16, 2027, with the remaining three quarters vesting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
par value financial
"shares of common stock, par value $0.0001, of the Issuer"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does Yarrow Bioscience (VYNE) report in Rebecca Frey’s Form 3?
Yarrow Bioscience reports that CEO Rebecca Frey beneficially holds a stock option over 878,194 shares of common stock. The option was received in a merger-related exchange and is reported as a holding rather than a new market transaction.
What is the exercise price and expiration date of Rebecca Frey’s option at Yarrow Bioscience (VYNE)?
The stock option has an exercise price of $6.1900 per share and expires on 2036-01-30. These terms were carried over when prior Yarrow options were converted into options for Yarrow Bioscience common stock in the merger.
How did the merger involving VYNE Therapeutics affect Rebecca Frey’s options reported for VYNE?
At the merger’s Effective Time, each prior Yarrow option held by Rebecca Frey was assumed and converted into an option for Issuer Common Stock. The options kept the same terms and conditions, now referencing Yarrow Bioscience, Inc. as the issuer.
What is the vesting schedule of Rebecca Frey’s stock option at Yarrow Bioscience (VYNE)?
The option vests over time: one quarter vests on January 16, 2027, with the remaining three quarters vesting in equal monthly installments over three years. Vesting requires Rebecca Frey’s continued service to Yarrow Bioscience on each vesting date.
What role does Rebecca Frey hold at Yarrow Bioscience (VYNE) in this Form 3?
Rebecca Frey is identified as a director and Chief Executive Officer of Yarrow Bioscience, Inc. The Form 3 records her initial beneficial ownership, specifically her stock option position, in connection with the completed merger and name change.